Sargassum pallidum polypeptide eye cream and preparation method thereof

Abstract

The invention relates to the technical field of cosmetics, and particularly discloses sargassum pallidum polypeptide eye cream and a preparation method thereof. The eye cream is prepared by taking low-molecular-weight sargassum pallidum polypeptide as a core active component, combining an emulsifier, a humectant and a stabilizer in a specific proportion, and performing a process of step-by-step melting of an oil phase and a water phase and homogeneous emulsification. According to the method, the stability of the paste is remarkably improved by optimizing the compatibility of the oil-phase component and the water-phase component. The obtained product is fine and uniform in paste, mild in pH value, easy to smear and good in stability, and fills the application blank of the sargassum pallidum active ingredient in eye care products.

Description

Technical Field

[0001] The invention relates to the technical field of cosmetics and preparation methods thereof, and in particular to an artemisia seaweed polypeptide eye cream and a preparation method thereof. Background Art

[0002] As one of the most vulnerable skin areas of the human body, the skin around the eyes is easily affected by the external environment and age factors, and may cause problems such as fine lines, sagging, and dryness. Therefore, the development of eye cream products with high anti-aging, moisturizing and repairing functions has always been a research hotspot in the cosmetics field. Peptide ingredients have been widely used in anti-aging skin care products in recent years due to their good biological activity and skin permeability. However, traditional peptide ingredients have problems such as large molecular weight, difficulty in transdermal absorption, poor stability and easy inactivation, or poor compatibility with other matrix ingredients, which limits the efficacy of the product. In addition, some peptide raw materials may have insufficient purity and safety risks (such as heavy metal or microbial contamination), which affect the stability of the formula and safety of use.

[0003] Sargassum pallidum, as a marine biological resource, is rich in a variety of active substances, but its application in cosmetics is still in the exploratory stage. In the prior art, there is no report on combining the polypeptide components derived from Sargassum pallidum with the eye cream matrix system. In the conventional eye cream preparation process, the emulsification process of the oil phase and the aqueous phase, the compatibility of the thickener and the active ingredient, and other problems are prone to cause the paste to have poor uniformity, easy stratification or poor application experience. Therefore, how to develop a Sargassum pallidum polypeptide eye cream with high stability, good skin feel and safety through reasonable component screening and process optimization has become a technical problem to be solved in this field.

[0004] In response to the above-mentioned problems, the present invention innovatively introduces high-purity Artemisia seaweed polypeptide into the eye cream system, and overcomes the difficult problem of balancing the retention of polypeptide activity, paste stability and user experience through the synergistic combination of matrix components and optimization of the preparation process, thus providing the market with an efficient, safe and easy-to-promote eye cream product solution. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide an artemisia seaweed polypeptide eye cream and a preparation method thereof in view of the deficiencies in the prior art.

[0006] In order to achieve the purpose of the present invention, the following technical means are specifically adopted:

[0007] A sargassum seaweed polypeptide eye cream, characterized by comprising the following components by mass fraction:

[0008] 2% - 5% of Sargassum polypeptide solution, 4% - 10% of cetyl alcohol, 2% - 6% or 10% of stearic acid, 0.2% - 1.0% of DL-α-tocopheryl acetate, 10% - 20% of jojoba oil, 10% - 20% of glycerol, 2% - 10% of PEG - 100 stearate, 0.3% of sodium hyaluronate, 0.2% - 0.4% or 0.8% - 1.0% of xanthan gum, 0.1% of disodium EDTA, with the balance being water;

[0009] The Sargassum polypeptide solution is an aqueous solution containing 50 mg / mL of Sargassum polypeptide, and the molecular weight of the Sargassum polypeptide ≤ 1000 Da.

[0010] The Sargassum polypeptide eye cream described above is characterized in that the molecular weight of the Sargassum polypeptide ≤ 1000 Da, the purity ≥ 99%, the loss on drying ≤ 5.0%, the ash content ≤ 5.0%, no pesticide residues and pathogenic bacteria are detected, and the total heavy metals ≤ 10 ppm.

[0011] The Sargassum polypeptide eye cream described above is characterized in that: the mass fraction of the stearic acid is 4% - 6%; the mass fraction of the cetyl alcohol is 4% - 8%.

[0012] The Sargassum polypeptide eye cream described above is characterized in that: the mass fraction of the DL-α-tocopheryl acetate is 0.6% - 0.8%; the mass fraction of the jojoba oil is 10% - 15%.

[0013] The Sargassum polypeptide eye cream described above is characterized in that: the mass fraction of the glycerol is 15% - 20%; the mass fraction of the PEG - 100 stearate is 4% - 8%.

[0014] The Sargassum polypeptide eye cream described above is characterized in that: the mass fraction of the xanthan gum is 0.2% - 0.4%.

[0015] The preparation method of the Sargassum polypeptide eye cream is characterized by including the following steps:

[0016] (1) Preparation of the oil phase: Mix cetyl alcohol, stearic acid, DL-α-tocopheryl acetate, and jojoba oil, heat and melt at 80 - 90 °C, and keep warm;

[0017] (2) Preparation of the water phase: Dissolve glycerol, PEG - 100 stearate, sodium hyaluronate, xanthan gum, disodium EDTA, and Sargassum polypeptide solution in water, heat to 80 - 90 °C for dissolution, and keep warm;

[0018] (3) Emulsification and homogenization: Slowly add the water phase to the oil phase, stir and mix, then homogenize at 2500 - 3500 rpm for 5 - 15 min, and cool to room temperature.

[0019] The Sargassum polypeptide eye cream described above is characterized in that it is used for eye contour skin care.

[0020] The Sargassum pallidum polypeptide described in the present invention is a light - colored powder. The particle size standard is that 100% can pass through an 80 - mesh sieve. The peptide content (on a dry basis) ≥ 99%, the molecular weight ≤ 1000 Da, the loss on drying ≤ 5.0%, the ash content ≤ 5.0%, no pesticide residues can be detected, the total heavy metal content ≤ 10 ppm, the arsenic content ≤ 10 ppm, the lead content ≤ 10 ppm, the total number of colonies ≤ 1000 cfu / g, the number of yeasts and molds ≤ 100 cfu / g, no Escherichia coli can be detected, no Salmonella can be detected, and no Staphylococcus can be detected.

[0021] Beneficial effects

[0022] The beneficial effects of the present invention are as follows:

[0023] For the first time, the present invention combines low - molecular - weight polypeptides (molecular weight ≤ 1000 Da) derived from Sargassum pallidum with an eye - care matrix system. By screening specific emulsifier and stabilizer ratios, a new eye - cream formula has been developed. While maintaining natural safety, this formula provides a new choice of active ingredients for anti - aging around the eyes, filling the blank in the application of Sargassum pallidum polypeptides in the cosmetics field. Specific embodiments

[0024] The technical solutions of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all of the embodiments. The description of at least one exemplary embodiment is actually only illustrative and in no way restricts the present invention and its application or use. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts belong to the scope of protection of the present invention.

[0025] Description of the Sargassum pallidum polypeptide used in the present invention: The manufacturer is Xi'an Mugo Biotechnology Co., Ltd., product batch number: MG - 2024081502. The appearance is a light - colored powder. The particle size standard is that 100% can pass through an 80 - mesh sieve. The peptide content (on a dry basis) is 99.07%, the molecular weight ≤ 1000 Da, the loss on drying is 0.79%, the ash content is 1.42%, no pesticide residues are detected, the total heavy metal content ≤ 10 ppm, the arsenic content ≤ 10 ppm, the lead content ≤ 10 ppm, the total number of colonies ≤ 1000 cfu / g, the number of yeasts and molds ≤ 100 cfu / g, no Escherichia coli is detected, no Salmonella is detected, and no Staphylococcus is detected.

[0026] Example 1 Screening of the composition of the blank - matrix eye cream

[0027] 1. Initially formulate the blank - matrix prescription

[0028] Combined with the general composition of the eye cream and the physicochemical properties of Sargassum polypeptides, the blank matrix prescription was preliminarily formulated as shown in Table 1.

[0029] Table 1 Preliminary formulation of the blank matrix

[0030]

[0031] 2. Preliminary preparation method

[0032] (1) Weigh all the raw materials in phase A separately, place them in clean beaker 1, heat and melt them in a constant temperature water bath at 85 °C, and keep them warm in the water bath for use as the oil phase.

[0033] (2) Weigh all the raw materials in phase B separately, place them in clean beaker 2, heat and melt them in a constant temperature water bath at 85 °C, and keep them warm in the water bath for use as the water phase.

[0034] (3) Under the water bath condition of 85 °C, slowly add the raw materials in phase B to phase A while stirring. After stirring evenly, homogenize at 3000 rpm for 10 min, and cool to room temperature to obtain the O / W type eye cream.

[0035] 3. The calculation and measurement methods of some evaluation indexes are as follows

[0036] 3.1 Sensory evaluation and stability determination

[0037] Randomly select 10 healthy skin volunteers to conduct sensory evaluation of the eye cream in the same environment. Take appearance, spreadability, moisturizing degree, and stability as the evaluation indexes. Appearance: The paste should be delicate, uniform, and without visible coarse particles to the naked eye. Spreadability: Whether it is easy to spread on the skin during the application process after applying ten circles. Moisturizing degree: The texture is fresh and not greasy. Stability: Centrifuge at 3000 r / min for 30 min, and check whether there is any layering phenomenon in the eye cream. The specific judgment criteria are shown in Table 2 below.

[0038] Table 2 Scoring criteria for sensory evaluation and stability determination

[0039]

[0040] 4. Single factor screening of the blank matrix prescription composition

[0041] 4.1 Investigation on the prescription dosage of stearic acid

[0042] Set different prescription addition amounts of stearic acid (2%, 4%, 6%, 8%, 10%). The dosages of other components in the prescription are shown in Table 1. Prepare according to the proposed preparation method, and conduct sensory and stability scoring on the creams with different amounts of stearic acid added above to determine the optimal addition amount of stearic acid. The experimental results are shown in Table 3 below.

[0043] Table 3 Results of single factor investigation on the prescription dosage of stearic acid

[0044] Prescription amount (%) Appearance score Spreading property score Moisturizing degree score Stability score Total score 2 21 5 20 24 70 4 24 3 21 22 70 6 23 8 22 25 78 8 21 6 18 21 66 10 20 11 20 21 72

[0045] As can be seen from the results in the above table, when the prescription dosage of stearic acid is 2 - 6% and 10%, the overall scores of the prescriptions are all good (>70 points), indicating that the prescription dosages of stearic acid at 2 - 6% and 10% are all qualified. At the same time, it is noted that the score is the highest when the prescription dosage of stearic acid is 6%. Therefore, the prescription dosage of stearic acid at 6% is temporarily selected for subsequent screening research.

[0046] 4.2 Investigation on the Prescription Dosage of Cetyl Alcohol

[0047] Fix the addition amount of stearic acid in the prescription at 6%, and investigate different addition amounts of cetyl alcohol in the prescription (2%, 4%, 6%, 8%, 10%). The dosages of other components in the prescription are shown in Table 1. Prepare using the proposed preparation method, and conduct sensory and stability scoring on the creams with different added amounts of cetyl alcohol to determine the optimal addition amount of cetyl alcohol. The experimental results are shown in Table 4 below.

[0048] Table 4 Results of Single - Factor Investigation on the Prescription Dosage of Cetyl Alcohol

[0049] Prescription amount (%) Appearance score Spreading property score Moisturizing degree score Stability score Total score 2 22 6 17 22 67 4 24 3 21 22 70 6 24 9 23 24 80 8 20 11 20 21 72 10 23 8 22 25 78

[0050] As can be seen from the results in the above table, when the prescription dosage of cetyl alcohol is 4 - 10%, the overall scores of the prescriptions are all good (>70 points), indicating that the prescription dosages of cetyl alcohol at 4 - 10% are all qualified. At the same time, it is noted that the score is the highest when the prescription dosage of cetyl alcohol is 6%. Therefore, the prescription dosage of cetyl alcohol at 6% is temporarily selected for subsequent screening research.

[0051] 4.3 Investigation on the Prescription Dosage of DL - α - Tocopherol Acetate

[0052] Fix the addition amounts of stearic acid and cetyl alcohol in the prescription at 6% respectively, and investigate different addition amounts of DL - α - tocopherol acetate in the prescription (0.2%, 0.4%, 0.6%, 0.8%, 1%). The dosages of other components in the prescription are shown in Table 1. Prepare using the proposed preparation method, and conduct sensory and stability scoring on the creams with different added amounts of DL - α - tocopherol acetate to determine the optimal addition amount of DL - α - tocopherol acetate. The experimental results are shown in Table 5 below.

[0053] Table 5 Results of Single - Factor Investigation on the Prescription Dosage of DL - α - Tocopherol Acetate

[0054] Prescription amount (%) Appearance score Spreading property score Moisturizing degree score Stability score Total score 0.2 21 11 19 20 71 0.4 20 12 18 21 71 0.6 23 9 21 18 71 0.8 22 14 20 24 80 1.0 21 10 20 20 71

[0055] As can be seen from the results in the above table, when the prescription dosage of DL-α-tocopheryl acetate is 0.2 - 1.0%, the overall scores of the prescriptions are all good (>70 points), indicating that the prescription dosages of DL-α-tocopheryl acetate from 0.2% to 1.0% are all qualified. At the same time, it is noted that the score is the highest when the prescription dosage of DL-α-tocopheryl acetate is 0.8%. Therefore, the prescription dosage of DL-α-tocopheryl acetate is temporarily selected as 0.8% for subsequent screening research.

[0056] 4.4 Investigation on the Prescription Dosage of Jojoba Oil

[0057] Fix the addition amounts of stearic acid and cetyl alcohol in the prescription at 6% each, and fix the addition amount of DL-α-tocopheryl acetate in the prescription at 0.8%. Investigate different addition amounts of jojoba oil in the prescription (10%, 12.5%, 15%, 17.5%, 20%). The amounts of other components in the prescription are shown in Table 1. Prepare using the proposed preparation method, and conduct sensory and stability scoring on the creams with different amounts of jojoba oil added above to determine the optimal addition amount of jojoba oil. The experimental results are shown in Table 6 below.

[0058] Table 6 Results of Single-Factor Investigation on the Prescription Dosage of Jojoba Oil

[0059] Prescription amount (%) Appearance score Spreading property score Moisturizing degree score Stability score Total score 10 21 16 22 24 83 12.5 19 11 21 21 72 15 23 12 19 22 76 17.5 22 15 19 20 76 20 20 8 20 23 71

[0060] As can be seen from the results in the above table, when the prescription dosage of jojoba oil is 10 - 20%, the overall scores of the prescriptions are all good (>70 points), indicating that the prescription dosages of jojoba oil from 10% to 20% are all qualified. At the same time, it is noted that the score is the highest when the prescription dosage of jojoba oil is 10%. Therefore, the prescription dosage of jojoba oil is temporarily selected as 10% for subsequent screening research.

[0061] 4.5 Investigation on the Prescription Dosage of Glycerol

[0062] Fix the addition amounts of stearic acid and cetyl alcohol in the prescription at 6%, fix the addition amount of DL-α-tocopheryl acetate in the prescription at 0.8%, and fix the addition amount of jojoba oil in the prescription at 10%. Investigate different addition amounts of glycerol in the prescription (10%, 12.5%, 15%, 17.5%, 20%). The amounts of other components in the prescription are shown in Table 1. Prepare using the proposed preparation method, and conduct sensory and stability scoring on the creams with different amounts of glycerol added above to determine the optimal addition amount of glycerol. The experimental results are shown in Table 7 below.

[0063] Table 7 Results of Single-Factor Investigation on the Prescription Dosage of Glycerol

[0064] Prescription amount (%) Appearance score Spreading property score Moisturizing degree score Stability score Total score 10 21 12 20 21 74 12.5 23 11 21 20 75 15 22 9 23 21 75 17.5 24 10 19 22 75 20 24 15 24 25 88

[0065] As can be seen from the results in the above table, when the prescription dosage of glycerol is 10 - 20%, the overall scores of the prescriptions are all good (>70 points), indicating that the prescription dosages of glycerol from 10% to 20% are all qualified. At the same time, it is noted that the score is the highest when the prescription dosage of glycerol is 20%. Therefore, the prescription dosage of glycerol is temporarily selected as 20% for subsequent screening studies.

[0066] 4.6 Investigation on the Prescription Dosage of Xanthan Gum

[0067] Fix the addition amounts of stearic acid and cetyl alcohol in the prescription at 6% each, fix the addition amount of DL-α-tocopherol acetate in the prescription at 0.8%, fix the addition amount of jojoba oil in the prescription at 10%, fix the addition amount of glycerol in the prescription at 20%, and investigate different addition amounts of xanthan gum in the prescription (0.2%, 0.4%, 0.6%, 0.8%, 1%). The dosages of other components in the prescription are shown in Table 1. Prepare using the proposed preparation method, and conduct sensory and stability scoring on the creams with different addition amounts of xanthan gum to determine the optimal addition amount of xanthan gum. The experimental results are shown in Table 8 below.

[0068] Table 8 Results of the Single-Factor Investigation on the Prescription Dosage of Xanthan Gum

[0069] Prescription amount (%) Appearance score Spreading property score Moisturizing degree score Stability score Total score 0.2 21 10 24 21 76 0.4 23 11 20 24 78 0.6 20 4 20 23 67 0.8 21 6 23 24 74 1.0 23 9 21 21 74

[0070] As can be seen from the results in the above table, when the prescription dosage of xanthan gum is 0.2 - 0.4% and 0.8 - 1.0%, the overall scores of the prescriptions are all good (>70 points), indicating that the prescription dosages of xanthan gum from 0.2% to 0.4% and 0.8% to 1.0% are all qualified. At the same time, it is noted that the score is the highest when the prescription dosage of xanthan gum is 0.4%. Therefore, the prescription dosage of xanthan gum is temporarily selected as 0.4% for subsequent screening studies.

[0071] 4.7 Investigation on the Prescription Dosage of PEG - 100 Stearate

[0072] Fix the addition amounts of stearic acid and cetyl alcohol in the prescription at 6% each, fix the addition amount of DL-α-tocopherol acetate in the prescription at 0.8%, fix the addition amount of jojoba oil in the prescription at 10%, fix the addition amount of glycerol in the prescription at 20%, fix the addition amount of xanthan gum in the prescription at 0.4%, and investigate different addition amounts of PEG - 100 stearate in the prescription (2%, 4%, 6%, 8%, 10%). The dosages of other components in the prescription are shown in Table 1. Prepare using the proposed preparation method, and conduct sensory and stability scoring on the creams with different addition amounts of PEG - 100 stearate to determine the optimal addition amount of PEG - 100 stearate. The experimental results are shown in Table 9 below.

[0073] Table 9 Results of the Single-Factor Investigation on the Prescription Dosage of PEG - 100 Stearate

[0074] Prescription amount (%) Appearance score Spreading property score Moisturizing degree score Stability score Total score 2 23 8 21 21 73 4 21 9 22 24 76 6 22 12 23 25 82 8 23 11 21 22 77 10 21 10 20 23 74

[0075] As can be seen from the results in the above table, when the prescription dosage of PEG - 100 stearate is 2 - 10%, the overall scores of the prescriptions are all good (>70 points), indicating that the prescription dosages of PEG - 100 stearate from 2 - 10% are all qualified. At the same time, it is noted that the score is the highest when the prescription dosage of PEG - 100 stearate is 6%. Therefore, the prescription dosage of PEG - 100 stearate is temporarily selected as 6% for subsequent screening research.

[0076] According to the investigation results of the above blank matrix prescription, the composition of the blank matrix prescription is determined as follows:

[0077] Table 10 Composition of the blank matrix prescription

[0078]

[0079] Note: The qualified range of the prescription dosage of stearic acid is 2 - 6% and 10%; the qualified range of the prescription dosage of cetyl alcohol is 4 - 10%; the qualified range of the prescription dosage of DL-α - tocopherol acetate is 0.2 - 1.0%; the qualified range of the prescription dosage of jojoba oil is 10 - 20%; the qualified range of the prescription dosage of glycerol is 10 - 20%; the qualified range of the prescription dosage of xanthan gum is 0.2 - 0.4% and 0.8 - 1.0%; the qualified range of the prescription dosage of PEG - 100 stearate is 2 - 10%.

[0080] Example 2 Investigation on the prescription addition amount of Sargassum polypeptide solution

[0081] Prepare an aqueous solution of Sargassum polypeptide with a concentration of 50 mg / mL, and add it to Phase B of the blank matrix prescription. Set different prescription addition amounts of Sargassum polypeptide solution (1%, 2%, 3%, 4%, 5%). The dosages of other components in the prescription are shown in Table 10. The water in Phase B is added last and made up to 100%. Prepare using the proposed preparation method, and conduct sensory and stability scoring on the creams added with different amounts of Sargassum polypeptide solution to determine the optimal addition amount of Sargassum polypeptide solution. The experimental results are shown in Table 11 below.

[0082] Table 11 Results of single - factor investigation on the prescription dosage of Sargassum polypeptide solution

[0083] Prescription amount (%) Appearance score Spreading property score Moisturizing degree score Stability score Total score 1 21 6 18 21 66 2 21 6 23 24 74 3 21 5 20 24 70 4 22 12 23 25 82 5 23 12 19 22 76

[0084] As can be seen from the results in the above table, when the prescription dosage of Sargassum polypeptide solution is 2 - 5%, the overall scores of the prescriptions are all good (>70 points), indicating that the prescription dosages of Sargassum polypeptide solution from 2 - 5% are all qualified. At the same time, it is noted that the score is the highest when the prescription dosage of Sargassum polypeptide solution is 4%.

[0085] Example 3 Performance evaluation of Sargassum polypeptide eye cream

[0086] 1. Physical and chemical properties

[0087] 1.1 Appearance and texture

[0088] It is a white milky paste with delicate and uniform texture and no granular feeling.

[0089] 1.2 pH value

[0090] Weigh 2 g of the eye cream (accurate to 0.1 g), add nine parts of test water that has been boiled and cooled, heat it to 40 °C, stir continuously, and cool it to room temperature for standby. Before measurement, first calibrate with two standard buffer solutions, rinse the electrode with water after calibration, then dry it with filter paper, carefully insert the electrode into the sample to immerse the electrode, wait for the pH meter reading to be stable, and record the reading.

[0091] Measurement results: 5.27, 5.28, 5.43.

[0092] 1.3 Stability test

[0093] (1) Centrifugation experiment: Transfer 1.5 g of the sample into a 2 mL EP tube, centrifuge at 3000 r / min for 30 min, and observe whether there is any layering in the moisturizing cream.

[0094] Result: There is no layering or oil-water separation phenomenon.

[0095] (2) Cold resistance experiment:

[0096] Set the refrigerator temperature to -24 °C, transfer 1.5 g of the sample into a 2 mL EP tube, place it in the refrigerator, and take it out after 24 h to observe whether there is any layering in the moisturizing cream.

[0097] Result: The paste remains uniform after returning to room temperature.

[0098] (3) Heat resistance experiment:

[0099] Set the temperature of the constant temperature incubator to 40 °C, transfer 1.5 g of the sample into a 2 mL EP tube, place it in the constant temperature incubator, and take it out after 24 h to observe whether there is any layering in the moisturizing cream.

[0100] Result: The paste remains uniform after returning to room temperature.

[0101] 2. Sensory evaluation

[0102] Through the blind test of 20 subjects, the results show that: 95% of the subjects think that the paste is easy to spread and absorb quickly, without a sticky feeling; 90% of the subjects recognize the moisturizing effect, and the firmness of the eye area skin is improved after use.

[0103] The above are only the preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention shall be included within the protection scope of the present invention.

Claims

1. A sargassum seaweed polypeptide eye cream, characterized in that: The following components are included in mass fraction: 2% to 5% of Artemisia seaweed polypeptide solution, 4% to 10% of cetyl alcohol, 2% to 6% or 10% of stearic acid, 0.2% to 1.0% of DL-α-tocopheryl acetate, 10% to 20% of jojoba oil, 10% to 20% of glycerol, 2% to 10% of PEG-100 stearate, 0.3% of sodium hyaluronate, 0.2% to 0.4% or 0.8% to 1.0% of xanthan gum, 0.1% of disodium EDTA, and the balance is water; The sargassum seaweed polypeptide solution is an aqueous solution containing 50 mg / mL of sargassum seaweed polypeptide, and the molecular weight of the sargassum seaweed polypeptide is ≤1000Da.

2. The sargassum seaweed polypeptide eye cream according to claim 1, characterized in that: The molecular weight of the sea wormwood polypeptide is ≤1000Da, the purity is ≥99%, the drying loss is ≤5.0%, the ash content is ≤5.0%, pesticide residues and pathogenic bacteria are not detected, and the total amount of heavy metals is ≤10ppm.

3. The sargassum seaweed polypeptide eye cream according to claim 1, characterized in that: The mass fraction of the stearic acid is 4% to 6%; the mass fraction of the cetyl alcohol is 4% to 8%.

4. The sargassum seaweed polypeptide eye cream according to claim 1, characterized in that: The mass fraction of the DL-α-tocopherol acetate is 0.6% to 0.8%; the mass fraction of the jojoba oil is 10% to 15%.

5. The sargassum seaweed polypeptide eye cream according to claim 1, characterized in that: The mass fraction of the glycerol is 15% to 20%; the mass fraction of the PEG-100 stearate is 4% to 8%.

6. The sargassum seaweed polypeptide eye cream according to claim 1, characterized in that: The mass fraction of the xanthan gum is 0.2% to 0.4%.

7. A method for preparing the Artemisia seagrass polypeptide eye cream according to any one of claims 1 to 6, characterized in that: The following steps are involved: (1) Preparation of oil phase: Cetyl alcohol, stearic acid, DL-α-tocopherol acetate and jojoba oil were mixed, heated to melt at 85±2°C, and kept warm; (2) Preparation of aqueous phase: dissolve glycerol, PEG-100 stearate, sodium hyaluronate, xanthan gum, disodium EDTA, and Artemisia seaweed polypeptide solution in water, heat to 85±2°C to dissolve, and keep warm; (3) Emulsification and homogenization: slowly add the water phase into the oil phase, stir and mix, homogenize at 3000 rpm for 10 min, and cool to room temperature.

8. The Artemisia seaweed polypeptide eye cream according to any one of claims 1 to 6, characterized in that: It is used for skin care around the eyes.

Images